


Journal Pre-proof

Impact of Allergic Rhinitis and Asthma on COVID-19 Infection, Hospitalization and Mortality

Jianjun Ren, PhD, Wendu Pang, MD, Yaxin Luo, PMH, Danni Cheng, MD, Ke Qiu, MD, Yufang Rao, MSC, Yongbo Zheng, PhD, Yijun Dong, MBBS, Jiajia Peng, MBBS, Yao Hu, MSC, Zhiye Ying, MSC, Haopeng Yu, PhD, Xiaoxi Zeng, PhD, Zhiyong Zong, PhD, Geoffrey Liu, MD, Deyun Wang, PhD, Gang Wang, PhD, Wei Zhang, MD, Wei Xu, PhD, Yu Zhao, MD, PhD



PII: S2213-2198(21)01202-2

DOI: <https://doi.org/10.1016/j.jaip.2021.10.049>

Reference: JAIP 3933

To appear in: *The Journal of Allergy and Clinical Immunology: In Practice*

Received Date: 29 June 2021

Revised Date: 21 October 2021

Accepted Date: 21 October 2021

Please cite this article as: Ren J, Pang W, Luo Y, Cheng D, Qiu K, Rao Y, Zheng Y, Dong Y, Peng J, Hu Y, Ying Z, Yu H, Zeng X, Zong Z, Liu G, Wang D, Wang G, Zhang W, Xu W, Zhao Y, Impact of Allergic Rhinitis and Asthma on COVID-19 Infection, Hospitalization and Mortality, *The Journal of Allergy and Clinical Immunology: In Practice* (2021), doi: <https://doi.org/10.1016/j.jaip.2021.10.049>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology

Impact of Allergic Rhinitis and Asthma on COVID-19 Infection, Hospitalization and Mortality

Jianjun Ren^{1,2,3,4#}, PhD, Wendu Pang^{1#}, MD, Yaxin Luo^{5#}, PMH, Danni Cheng¹, MD, Ke Qiu¹, MD, Yufang Rao¹, MSC, Yongbo Zheng¹, PhD, Yijun Dong¹, MBBS, Jiajia Peng¹, MBBS, Yao Hu², MSC, Zhiye Ying², MSC, Haopeng Yu², PhD, Xiaoxi Zeng², PhD, Zhiyong Zong⁶, PhD, Geoffrey Liu^{7,8†}, MD, Deyun Wang^{9†}, PhD, Gang Wang^{10†}, PhD, Wei Zhang^{2*}, MD, Wei Xu^{3*}, PhD, Yu Zhao^{1,2*}, MD, PhD

¹ Department of Oto-Rhino-Laryngology, West China Hospital, Sichuan University, Chengdu, China

² West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, China

³ Department of Biostatistics, Princess Margaret Cancer Centre and Dalla Lana School of Public Health, Toronto, Ontario, Canada;

⁴ Department of Oto-Rhino-Laryngology, Langzhong People's Hospital, Langzhong, China

⁵ Department of Epidemiology and Biostatistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China

⁶ Department of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China

⁷ Medical Oncology and Hematology, Princess Margaret Cancer Centre, and Department of Medicine, University of Toronto

⁸ Department of Medicine, Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Canada

⁹ Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore, Singapore

¹⁰ Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, China

#These authors contributed equally to this work

† Co-senior authors: Geoffrey Liu and Deyun Wang

* Corresponding author:

Wei Zhang, West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, China, weizhang27@163.com, +86-028-85421671

Wei Xu, Department of Biostatistics, Princess Margaret Cancer Centre, 10-511, 610 University Avenue Toronto, Toronto, Ontario, Canada; Email: Wei.Xu@uhnresearch.ca, 1-416-9464497

Yu Zhao, 1 Department of Oto-Rhino-Laryngology, West China Hospital, Sichuan University, Chengdu, China, Email: yutzhao@VIP.163.com, +86-028-85421671

Funding: This work was supported by West China Hospital, Sichuan University, 2019HXFH003, ZYJC21027; Key Research and Development Support Programmes of Chengdu Science and Technology Bureau: 2019-YF05-00461-SN; the Fundamental Research Funds for the Central Universities: Z20201013, 2019HXBH079, 2020SCU12049, ZYJC21027, GSALK2020021; The Scientific and Technological Projects of Sichuan Province: 2020YFH0090, 2020YFS0111; the Science and Technology Projects of Sichuan Health and Health Commission: 20PJ030; China Postdoctoral Science Foundation: 2020M673250; National Natural Science Foundation of China: 82002868. GL is supported by Alan B. Brown Chair and Lusi Wong Family Fund.

Conflict of interest

The authors declare that they have no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Ethics committee approval:

UK Biobank ethical approval was from the North West Multi-centre Research Ethics Committee.

Abstract**Background**

It remains unclear if patients with AR and/or asthma are susceptible to COVID-19 infection, severity and mortality.

Objective

To investigate the role of AR and/or asthma in COVID-19 infection, severity, and mortality, and assess whether long-term AR and/or asthma medications affected the outcomes of COVID-19.

Methods

Demographic and clinical data of 70,557 adult participants completed SARS-Cov-2 testing between March 16 and December 31, 2020 in the UK Biobank were analyzed. The rates of COVID-19 infection, hospitalization and mortality in relation to preexisting AR and/or asthma were assessed based on adjusted generalized linear models. We further analyzed the impact of long-term AR and/or asthma medications on the risk of COVID-19 hospitalization and mortality.

Results

AR patients of all ages had lower positive rates of SARS-Cov-2 tests (RR:0.75, 95% CI: 0.69-0.81, $p<0.001$), with lower susceptibility in males (RR: 0.74, 95%CI: 0.65-0.85, $p<0.001$) than females (RR: 0.8, 95% CI: 0.72-0.9, $p<0.001$). However, similar effects of asthma against COVID-19 hospitalization were only major in participants aged <65 (RR:0.93, 95% CI: 0.86-1, $p=0.044$) instead of elderlies. In contrast, asthma patients tested positively had higher risk

of hospitalization (RR:1.42, 95% CI: 1.32-1.54, $p<0.001$). Neither AR nor asthma had impact on COVID-19 mortality. None of conventional medications for AR or asthma, e.g., antihistamines, corticosteroids or β_2 adrenoceptor agonists showed association with COVID-19 infection or severity.

Conclusion

AR (all ages) and asthma (aged<65) act as protective factors against COVID-19 infection, while asthma increase risk for COVID-19 hospitalization. None of the long-term medications had significant association with infection, severity and mortality of COVID-19 among patients with AR and/or asthma.

Keywords

COVID-19, Allergic Rhinitis, Asthma, Long-term medications, Glucocorticoids

Abbreviations

Corona Virus Disease 2019 (COVID-19)

Chronic obstructive pulmonary disease (COPD)

Allergic rhinitis (AR)

UK Biobank (UKB)

Public Health England (PHE)

International Classification of Diseases codes (ICD codes)

Inhaled corticosteroids (ICS)

Body mass index (BMI)

Standard deviation (SD)

Relative risks (RRs)

Confidence intervals (CIs)

Angiotensin-converting enzyme 2 (ACE2)

Highlight Box

What is already known about this topic?

In different studies, whether asthma and allergic rhinitis acting as independent risk factors for COVID-19 remains controversial.

What does this article add to our knowledge?

AR (all ages) and asthma (aged<65) act as protective factors against COVID-19 infection, while asthma increase the risk for hospitalization. None of the long-term medications had significant association with infection, severity and mortality of COVID-19 among patients with AR and/or asthma.

How does this study impact current management guidelines

We provided new insights on the association between allergic diseases and COVID-19 prevalence and outcomes. We suggested more attention should be paid to the education and primary care of elderly asthmatic patients diagnosed with COVID-19, including active treatment of comorbidities.

Introduction

The emergence of COVID-19 has had a huge impact on population health globally. As of May 9th, 2021, there have been more than 157 million confirmed COVID-19 cases worldwide and over 3.2 million deaths were attributed to the pandemic ([https://covid19.who.int./](https://covid19.who.int/)). It has been reported that some underlying diseases such as dementia, pneumonia, depression, diabetes, atrial fibrillation, chronic obstructive pulmonary disease (COPD) and hypertension^[1], as well as high cytokine, lactate dehydrogenase level^[2] and ages could affect the prevalence and outcomes of COVID-19.

Allergic rhinitis (AR) and asthma are common and underestimated respiratory diseases and often simultaneously occur as united airway disease^[3-5]. Whether AR and asthma acting as independent risk factor for the infection, hospitalization and mortality of COVID-19 remains controversial. It was reported that AR/asthma patients were often exacerbated by viral respiratory infections^[6, 7]. A Korean nationwide cohort study reported that AR and asthma increased the susceptibility and severity of COVID-19^[8]. On the contrary, other reports suggested that asthma did not pose a threat to the diagnosis and severity of COVID-19^[9-12]. Moreover, some meta-analyses even concluded that asthma was considered as an independent protective factor for the death of patients with COVID-19^[13-15].

Our current study aimed to explore the role of AR and/or asthma in the risk of infection, severity and mortality of COVID-19 based on a large prospective cohort in UK Biobank, and to evaluate whether long-term medications for AR and/or asthma would affect the clinical manifestation and outcomes of COVID-19.

Methods

Database information

UK Biobank (UKB) is a national prospective cohort with very large and detailed data from over 500,000 participants aged 40–69 years when recruited at baseline (in 2006–2010), which ensured a wide distribution across all exposures to provide reliable associations between personal characteristics and health outcomes^[16]. SARS-Cov-2 testing results data were offered to UKB by Public Health England (PHE). UK Biobank ethical approval was from the North West Multi-centre Research Ethics Committee. The current analysis was approved under the UKB application (Applicant Number: 69718).

Study population

UKB participants with matching SARS-Cov-2 results (whether reported as positive or negative for SARS-Cov-2) tested between March 16th 2020 and December 31st, 2020 in England were examined. We excluded individuals with 1) who died before the pandemic (set as February 1st, 2020); 2) whose location belonged to UKB assessment centers in Scotland and Wales (where no SARS-CoV-2 testing data were available); and 3) who were diagnosed with AR and/or asthma after February 1st, 2020, which was set as the beginning of the pandemic^[1].

Exposure variables and covariables

AR was defined as either self-reported AR history from baseline questionnaires or the International Classification of Diseases codes (ICD-10 codes: J30.1, J30.2, J30.3, J30.4; or ICD-9 codes: 460,477). Asthma was defined as either self-reported asthma history from baseline questionnaires or ICD codes (ICD-10 codes: J45; or ICD-9 codes: 493).

Medication data of UK Biobank participants were available from a verbal interview by a trained nurse on prescription medications including type and number of medications. The long-term medications were defined as regular medications taken weekly and monthly, as opposed to the short-term medications. We summarized different types of medications such as antihistamine, glucocorticoids, inhaled corticosteroids (ICS) and β 2 adrenoceptor agonists according to their coding in Table E1.

Covariables included gender, age, Townsend deprivation index, education, body mass index (BMI), ethnic background, smoking status, alcohol drinking status, current employment status and preexisting comorbidities^[1, 17]. Age was defined as baseline age plus the duration of interval before inclusion. Preexisting comorbidities considered in this study included cancer diagnosed by doctor (self-report in questionnaires), fracture resulting from simple fall (self-report in questionnaires), diabetes mellitus (ICD-10 codes E10, E11, E12, E13, E14), chronic diseases of the circulatory system (ICD-10 codes I05-I09, I10-I15, I20-I25, I26-I28, I60-I69), chronic lower respiratory diseases (ICD-10 codes J40, J41, J42, J43, J44, J47 or ICD-9 codes 490, 491, 492, 496, 494), diseases of esophagus, stomach and duodenum (ICD-10 codes K20, K21, K25, K26, K27, K28, K29, K30 or ICD-9 codes 530, 531, 532, 533, 534, 535, 5368), renal failure (ICD-10 codes N17, N18, N19 or ICD-9 codes 584, 585), dementia (ICD-10 codes F00, F01, F02, F03, G30 or ICD-9 codes 2901), liver disease (K72 Hepatic failure, not elsewhere classified, K74, 5712, 5715, 5716 fibrosis and cirrhosis of liver), arthritis (ICD-10 codes M00, M01, M02, M03, M05, M06, M07, M08, M09, M10, M11, M12, M13, M14) and certain immune disorders (ICD-10 codes D80, D81, D82, D83, D84, D86, D89). However, due

to the limited number of patients who had liver diseases (n=609, less than 1%), we excluded liver disease when doing the adjustment.

Outcomes

The definition of COVID-19 infection referred to at least one positive testing result of SARS-CoV-2. When exploring the severity and mortality of COVID-19, we focused on the participants who had confirmed COVID-19. SARS-CoV-2-positive patients who progressed to hospitalization were considered as “severe COVID-19”^[10]. To identify patients died of COVID-19, we used mortality data provided by UK Biobank using the ICD10 identifier of U07.1 (underlying COVID-19 cause of death).

Statistics analyses

Continuous variables were presented as mean and standard deviation (SD), and categorical variables were presented as frequencies and percentages. Student's *t*-test was used for continuous variable comparisons and chi-square test for categorical variable comparisons in order to assess the differences among groups. Generalized linear models (robust Poisson model) were generated to evaluate the correlation of AR and/or asthma with COVID-19 outcomes (including prevalence, hospitalization rate and mortality), shown as relative risks (RRs) and 95% confidence intervals (CIs). Smoking status consisted of two variables: smoking experience, categorized as current, former, and never smoker; and pack year, defined as the product of the average number of cigarette packs (regular size, 20 cigarettes) smoked per day and the total number of years smoked. According to the variable distribution, observation value and association of smoking participants^[18], multiple imputation using chained equations that

provided multiple predictions for each missing value had been conducted to impute the missing data of smoking pack year (n=11,391).

Four models were constructed according to the adjustments of factors: i. Model* was a univariate model without adjustment; ii. Model** adjusted gender and age additionally; iii. Model*** was further adjusted for potential confounders, including Townsend deprivation index, education, current employment status, BMI, ethnic background, smoking and drinking status; iv. Model**** added preexisting comorbidities mentioned above as adjustments based on Model***. Above four models were analyzed simultaneously for AR group, asthma group, AR and asthma group, respectively, and the reference was the healthy control group for all relevant analyses.

Medication analyses were conducted for participants who had either AR or asthma, and participants who had AR or asthma but never used those medicines served as the controls in corresponding analysis.

For subgroup analyses, Model**** was constructed for participants stratified by gender (female or male), age (< 65 or ≥ 65 years old), BMI (≤ 30 or > 30), ethnic background (white or non-white) and smoking (never, previous or current). Preexisting dementia was reported to be associated with dramatically increasing risk of COVID-19 hospitalization and death (OR = 7.30)^[1] due to the APOE e4 genotype^[19], hence sensitivity analysis was conducted for participants without dementia to assess the robustness of our results.

In order to conduct a more in-depth analysis for asthma, asthma participants were further divided into allergic asthma and non-allergic asthma groups, and the Model**** was applied

for the sub-analysis. Allergic asthma was defined as asthma with any allergic disease (hayfever, allergy rhinitis or eczema, defined as ICD-10 codes: L20 and J30.1-J30.4 or self-report in questionnaires)^[10], and non-allergic asthma referred to asthma without any allergic disease. The reference was healthy control group without asthma or allergic diseases. In another sub-analysis, we explored the differences in the outcomes of COVID-19 between asthma patients with/without COPD (COPD was defined as the following ICD-10 codes: J43, J44 or self-report in questionnaires) and participants without asthma or COPD (reference group).

All analyses were performed by R 3.6.3 (R Development Core Team, Vienna, Austria), and $P < 0.05$ was considered for statistical significance.

Results

Patient characteristics

As shown in Table 1 and Table E2, there were 70,557 participants tested SARS-CoV-2, and 15,690 of them had at least one SARS-CoV-2 positive test. Among them, 4,915 patients were hospitalized due to the COVID-19, and 636 patients died of COVID-19. For analysis, we classified all participants into four groups of AR only (n=3,201), asthma only (n=8,624), AR and asthma (n=1,407), and control (neither AR nor asthma, n=57,325). The mean age of COVID-19 patients was 64.4 years, *versus* 68.7 years for those with non-COVID-19. Similarly, hospitalized patients with COVID-19 (mean age: 68 years *vs.* 62.8 years of non-hospitalized patients) or COVID-19-related death (mean age: 74 years *vs.* 64 years of non-death patients) were more likely to occur in the older participants than the younger, respectively.

The effect of AR and asthma on the infection of COVID-19

As shown in Table 2 and Figure 1, AR represented a protective effect against COVID-19 infection (RR: 0.75, 95%CI: 0.69-0.81, $p<0.001$), and this benefit was consistently observed (RR: 0.78, 95% CI: 0.71-0.85, $p<0.001$) after adjustment for gender, age, Townsend deprivation index, education, current employment status, BMI, ethnic background, smoking status and alcohol drinking status, and preexisting comorbidities by Model****. The protective effect of AR on COVID-19 infection was similar if patients had comorbid asthma (RR: 0.81, 95% CI: 0.73-0.92, $p=0.001$). However, the protective effect of asthma alone against the COVID-19 infection was not significant after adjustment (RR: 0.96, 95% CI: 0.91-1.01, $p=0.109$). Table E3 reported the association of AR and/or asthma with COVID-19 infection,

hospitalization and mortality, after adjustment for different covariates.

The effect of AR and asthma on the severity and mortality of COVID-19

As shown in Table 2, among those participants with positive SARS-CoV-2 test, AR did not significantly affect the hospitalization rate of COVID-19 after covariate adjustments (RR: 0.95, 95% CI: 0.79-1.13, $p=0.548$). On the contrary, asthma was a risk factor for the COVID-19 hospitalization (RR: 1.1, 95% CI: 1.01-1.19, $p=0.032$). Neither AR nor asthma had a significant effect on COVID-19 mortality after covariate adjustments for Townsend deprivation index, education, employment, BMI, ethnic background, smoking status, drinking status and preexisting comorbidities.

The effects of long-term medications for AR and/or asthma on infection, hospitalization and mortality of COVID-19.

We summarized four main long-term medication types that patients commonly used for control symptoms of AR or asthma, including β_2 adrenoceptor agonists, antihistamine, systemic glucocorticoids, and corticosteroid nasal sprays (CNS). As shown in Table 3 and Figure 2, due to the limited sample size (Table E4), none of these medications showed significant impact on infection, severity and mortality of COVID-19 among patients with AR and/or asthma.

We further conducted subgroup analyses for the most commonly used types of CNS (beclomethasone and fluticasone propionate), short-acting β_2 adrenoceptor agonists (SABA) and long-acting β_2 adrenoceptor agonists (LABA), shown in Table E5. However, due to the limited number of COVID-19 patients taking certain medicines chronically, none of these were

associated with the infection, hospitalization or mortality of COVID-19 after adjustments for other covariates ($p>0.05$).

Subgroup analyses for different clinical factors potentially affecting the infection and severity of COVID-19

As shown in Table E6, we evaluated the effects of different covariates on the infection, severity and mortality of COVID-19. Our results revealed that preexisting comorbidities (such as dementia, circulatory diseases, etc) were important variables that affecting the infection and severity of COVID-19 (Model****).

We further carried out multivariable subgroup analyses for the factors of gender, age, BMI, ethnics and smoking status to explore their individual effects on the infection and severity of COVID-19 (Table E7). With respect to COVID-19 infection and hospitalization, it was worth noting that when stratified participants by ages, asthma demonstrated a potential protective effect against COVID-19 infection in younger participants (aged<65 years, RR: 0.93, 95% CI: 0.86-1, $p=0.044$), but this effect on the elderly participants was not significant (aged $\geq$ 65 years, RR:1.02, 95% CI: 0.95-1.1, $p=0.59$). Compared with those never or previous smokers, current smokers with AR and asthma had a higher risk of COVID-19-related hospitalization (RR:1.98, 95% CI: 1-3.9, $p=0.049$).

Sub-analyses for Patients with Asthma

We further compared the differences in COVID-19 infection/outcomes between patients with allergic and non-allergic asthma (Table E8) and between asthma patients with and without COPD (Table E9), respectively. No significant difference between allergic and non-allergic asthma was observed in our results. In line with the above results, both of them reduced the

infection risk of COVID-19, while neither of them presented significant association with the COVID-19 hospitalization and mortality. Asthma patients without COPD had a slightly protective effect against COVID-19 infection, but such patients had an increased hospitalization risk of COVID-19.

Sensitivity Analysis

Some studies have shown that dementia had a striking association with COVID-19 related hospitalizations and deaths^[1]. We therefore performed sensitivity analyses by excluding participants with preexisting dementia (n=1,876) to evaluate the robustness of our results (Table E10). We observed consistent results that participants with AR (with/without asthma) had lower risk of COVID-19 infection, however, asthma patients with positive SARS-CoV-2 had higher risk of progression to hospitalized COVID-19.

Discussion

After evaluating 70,557 participants in UKB, our results showed that AR was a major protective factor from infecting COVID-19 after covariate adjustments. Asthma also showed a weak association with lower COVID-19 infection risk although it did not reach a statistical significance. It is noteworthy that this trend of asthma on COVID-19 infection was driven primarily in younger participants (aged <65 years), but not in the elderly participants (aged $\geq$ 65 years). Nonetheless, having a diagnosis of asthma was associated with a greater chance of COVID-19 hospitalization across all ages, even after covariate adjustments, whereas AR had no impact on COVID-19 hospitalizations. Although it is hard to make firm conclusions due to the limited number of deaths related to COVID-19, neither AR nor asthma was associated with COVID-19 mortality. None of the long-term medications for AR/asthma had some effects on the infection, hospitalization and mortality of COVID-19 after covariate adjustments.

We consider the reason why patients with AR (of all ages) or asthma (among younger participants) were associated with lower positive rate of SARS-CoV-2 test results. Angiotensin-converting enzyme 2 (ACE2) is the receptor for the attachment and entry of SARS-CoV-2 into the host cells^[20]. It has been reported that allergen provocation of respiratory tract would induce allergic airway inflammation which resulted in a decrease of ACE-2 expression, indicating that allergic inflammation may of great relevance to reduce the risk of COVID-19 infection^[11, 21, 22]. In addition, allergen-specific T cells may recruit a faster and more efficient memory-type response to deal with heterologous SARS-CoV-2 epitopes, which may provide significant advantages for patients with allergic diseases^[23, 24]. However, this protective effect of asthma

on COVID-19 infection was mainly observed in patients who were younger than 65 years in our study. The exact reason is unclear but we speculated that it might attribute to the decline in lung function and immunity with age^[25], which could lead to poorer prognoses^[26, 27].

It is interesting that AR and asthma exhibited distinct effects on COVID-19 hospitalization in our study, of which asthma was a risk factor while the influence of AR was not statistically notable. One potential reason is that SARS-CoV-2 impacts the lung parenchyma, so the additional impact of lower airway disease with asthma (and not with AR) could lead to a synergistically worsened clinical condition (i.e. rapid deterioration)^[28], further, asthma patients may have more pulmonary comorbidities which affect the disease outcomes. By contrast, AR (upper airways) is a disease more confined to the nose. Consistent with the findings here, some studies have also proposed that if SARS-CoV-2 succeeded to establish clinical manifestations in patients with asthma, the risk of disease progression is higher^[23]. The possible reasons given in these studies are as the following: 1) respiratory viruses provoke the local inflammatory cascades processed by T-lymphocyte trafficking, and induce the disruption of the bronchial defense system activated by resident monocytes^[29]. 2) respiratory viruses can change the composition of the airway microbiota and promote the growth of pathogens which may contribute to asthma exacerbations^[30]. (3) decreased antiviral function of eosinophils during respiratory viral infections in asthmatic patients may have a potential impact on virus-induced asthma exacerbations^[31].

Bloom et al. analyzed the data from Clinical Characterisation Protocol UK (CCP-UK) study and revealed that compared with patients without asthma, asthma patients with COVID-

19 were more likely to receive critical care during hospitalization^[32]. Several independent studies have observed a potential association between asthma phenotypes and COVID-19-related outcomes. According to the results of Zhu et al., nonallergic asthma was significantly associated with severe COVID-19, while allergic asthma had no statistically significant association with severe COVID-19. They also reported that this significant association persisted regardless of whether asthma patients had COPD or not^[10]. However, we did not observe such differences between allergic and non-allergic rhinitis. Although our research data came from the same UK Biobank database, the confounders we adjusted for and the populations we included were different. In our current study, we excluded participants who did not have SARS-cov-2 testing results, while these participants were considered as SARS-cov-2 negative in their study.

Another English cohort study (QResearch database) reported that COVID-19 patients with COPD or asthma had an increased risk of hospitalization and death^[33]. However, our results did not observe such trends, mainly due to the different population cohort we studied. Another Chinese study indicated that COPD and asthma were both important risk factors for poor clinical outcomes (such as needing invasive ventilation, admission to the intensive care unit, or death within 30 days after hospitalization) in patients with COVID-19^[34]. In contrast, our results showed statistically significant relationships only between the hospitalization rate of COVID-19 and asthma comorbidity.

The effect of glucocorticoid on the risk of susceptibility, severity and mortality of COVID-19 was controversial. Recent studies reported that glucocorticoid such as ciclesonide might

decrease the risk of susceptibility of COVID-19^[35-37]. However, our results did not observe that long-term use of antihistamine, systemic glucocorticoids or glucocorticoid nasal sprays was beneficial to the COVID-19 infection or prognosis. Similarly, Aveyard et al. reported that the use of glucocorticoids was not associated with the severity of COVID-19^[33]. And Schultze et al. also reported that long-term use of glucocorticoids would not reduce COVID-19-related mortality in patients with asthma or COPD^[38].

Although the advent of our study provided new insights into the association between allergic diseases and the prevalence and outcomes of COVID-19, a few limitations still existed. First, the UKB may have a healthy volunteer selection bias in participants subgroups who were older, female, or lived in less socioeconomically deprived areas^[39]. Second, the sample size for assessing COVID-19 related mortality in AR/asthma patients who had taken long-term medications was very small (126/2624), limiting our study power to detect differences related to medication use. Third, comorbidity data of participants were obtained from the baseline interviews and hospitalization information, but the current status of diseases remained unknown; the impact on our association is unknown, as some patients could have already taken off medications once remission has been achieved, while others had flare ups of their disease during the pandemic period. Fourthly, we have to use an imperfect surrogate for severity of COVID-19, namely COVID-19 hospitalizations, knowing that some patients with severe diseases may have been assumed to have COVID-19 infection and not tested, while some hospitalizations may have been misclassified due to other major disorders rather than COVID-19. Finally, our analyses did not take into account changes in participant behaviour. It is thus

still possible that participants with AR or younger asthmatic patients were either more careful about their own COVID-19 exposures or more afraid to present with COVID-19-like symptoms, and therefore were more likely to wear masks or adhere to social distancing.

In summary, AR (in all ages) is associated with lower rates of COVID-19 infection, but not with the severity and mortality of COVID-19. Similar protective effect in asthma patients, whatever allergic asthma or non-allergic asthma is observed only in those aged less than 65 years, but not in the elderlies (aged ≥ 65 years). In asthmatic patients with confirmed COVID-19, there is a higher risk of hospitalization than healthy controls.

Reference

- 1 Atkins JL, Masoli JAH, Delgado J, Pilling LC, Kuo CL, Kuchel GA et al. Preexisting Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort. *J Gerontol A Biol Sci Med Sci* 2020; 75 (11): 2224-2230.
- 2 Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol* 2020; 146 (1): 110-118.
- 3 Khan DA. Allergic rhinitis and asthma: epidemiology and common pathophysiology. *Allergy Asthma Proc* 2014; 35 (5): 357-361.
- 4 Tohidinik HR, Mallah N, Takkouche B. History of allergic rhinitis and risk of asthma; a systematic review and meta-analysis. *World Allergy Organ J* 2019; 12 (10): 100069.
- 5 Nae A, Hinchion K, Keogh IJ. A fifteen-year review of skin allergy testing in Irish patients with symptomatic rhinitis. *World J Otorhinolaryngol Head Neck Surg* 2021; 7 (4): 338-343.
- 6 Papadopoulos NG, Christodoulou I, Rohde G, Agache I, Almqvist C, Bruno A et al. Viruses and bacteria in acute asthma exacerbations--a GA² LEN-DARE systematic review. *Allergy* 2011; 66 (4): 458-468.
- 7 Liu S, Zhi Y, Ying S. COVID-19 and Asthma: Reflection During the Pandemic. *Clin Rev Allergy Immunol* 2020; 59 (1): 78-88.
- 8 Yang JM, Koh HY, Moon SY, Yoo IK, Ha EK, You S et al. Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study. *J Allergy Clin Immunol* 2020; 146 (4): 790-798.
- 9 Calmes D, Graff S, Maes N, Frix AN, Thys M, Bonhomme O et al. Asthma and COPD Are Not Risk Factors for ICU Stay and Death in Case of SARS-CoV2 Infection. *J Allergy Clin Immunol Pract* 2021; 9 (1): 160-169.
- 10 Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA, Jr., Liang L. Association of asthma and its genetic predisposition with the risk of severe COVID-19. *J Allergy Clin Immunol* 2020; 146 (2): 327-329.e324.
- 11 Jackson DJ, Busse WW, Bacharier LB, Kattan M, O'Connor GT, Wood RA et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. *J Allergy Clin Immunol* 2020; 146 (1): 203-206.e203.
- 12 Robinson LB, Wang L, Fu X, Wallace ZS, Long AA, Zhang Y et al. COVID-19 severity in asthma patients: a multi-center matched cohort study. *J Asthma* 2021: 1-14.
- 13 Shi L, Xu J, Xiao W, Wang Y, Jin Y, Chen S et al. Asthma in patients with coronavirus disease 2019: A systematic review and meta-analysis. *Ann Allergy Asthma Immunol* 2021.
- 14 Sunjaya AP, Allida SM, Di Tanna GL, Jenkins C. Asthma and risk of infection, hospitalization, ICU admission and mortality from COVID-19: Systematic review and meta-analysis. *J Asthma* 2021: 1-14.
- 15 Terry PD, Heidel RE, Dhand R. Asthma in Adult Patients with COVID-19. Prevalence and Risk of Severe Disease. *Am J Respir Crit Care Med* 2021; 203 (7): 893-905.
- 16 Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J et al. UK biobank: an

- open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med* 2015; 12 (3): e1001779.
- 17 Fan X, Liu Z, Miyata T, Dasarathy S, Rotroff DM, Wu X et al. Effect of Acid Suppressants on the Risk of COVID-19: A Propensity Score-Matched Study Using UK Biobank. *Gastroenterology* 2021; 160 (1): 455-458.e455.
 - 18 Bellou V, Belbasis L, Evangelou E. Tobacco Smoking and Risk for Pulmonary Fibrosis: A Prospective Cohort Study from the UK Biobank. *Chest* 2021.
 - 19 Kuo CL, Pilling LC, Atkins JL, Masoli JAH, Delgado J, Kuchel GA et al. APOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort. *J Gerontol A Biol Sci Med Sci* 2020; 75 (11): 2231-2232.
 - 20 Wakabayashi M, Pawankar R, Narazaki H, Ueda T, Itabashi T. Coronavirus disease 2019 and asthma, allergic rhinitis: molecular mechanisms and host-environmental interactions. *Curr Opin Allergy Clin Immunol* 2021; 21 (1): 1-7.
 - 21 Song J, Zeng M, Wang H, Qin C, Hou HY, Sun ZY et al. Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19. *Allergy* 2021; 76 (2): 483-496.
 - 22 Kimura H, Francisco D, Conway M, Martinez FD, Vercelli D, Polverino F et al. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. *J Allergy Clin Immunol* 2020; 146 (1): 80-88.e88.
 - 23 Skevaki C, Karsonova A, Karaulov A, Xie M, Renz H. Asthma-associated risk for COVID-19 development. *J Allergy Clin Immunol* 2020; 146 (6): 1295-1301.
 - 24 Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell* 2020; 181 (7): 1489-1501.e1415.
 - 25 Boonpiyathad T, Sözen ZC, Satitsuksanoa P, Akdis CA. Immunologic mechanisms in asthma. *Semin Immunol* 2019; 46: 101333.
 - 26 Tammola M, Won HK, Ilmarinen P, Jung H, Tuomisto LE, Lehtimäki L et al. Relationship between age and bronchodilator response at diagnosis in adult-onset asthma. *Respir Res* 2020; 21 (1): 179.
 - 27 De Marco R, Locatelli F, Cerveri I, Bugiani M, Marinoni A, Giammanco G. Incidence and remission of asthma: a retrospective study on the natural history of asthma in Italy. *J Allergy Clin Immunol* 2002; 110 (2): 228-235.
 - 28 Samitas K, Carter A, Kariyawasam HH, Xanthou G. Upper and lower airway remodelling mechanisms in asthma, allergic rhinitis and chronic rhinosinusitis: The one airway concept revisited. *Allergy* 2018; 73 (5): 993-1002.
 - 29 Edwards MR, Strong K, Cameron A, Walton RP, Jackson DJ, Johnston SL. Viral infections in allergy and immunology: How allergic inflammation influences viral infections and illness. *J Allergy Clin Immunol* 2017; 140 (4): 909-920.
 - 30 Novak N, Cabanillas B. Viruses and asthma: the role of common respiratory viruses in asthma and its potential meaning for SARS-CoV-2. *Immunology* 2020; 161 (2): 83-93.
 - 31 Sabogal Piñeros YS, Bal SM, Dijkhuis A, Majoor CJ, Dierdorp BS, Dekker T et al. Eosinophils capture viruses, a capacity that is defective in asthma. *Allergy* 2019;

- 74 (10): 1898-1909.
- 32 Bloom CI, Drake TM, Docherty AB, Lipworth BJ, Johnston SL, Nguyen-Van-Tam JS et al. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. *Lancet Respir Med* 2021; 9 (7): 699-711.
 - 33 Aveyard P, Gao M, Lindson N, Hartmann-Boyce J, Watkinson P, Young D et al. Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study. *Lancet Respir Med* 2021; 9 (8): 909-923.
 - 34 Guan WJ, Liang WH, Shi Y, Gan LX, Wang HB, He JX et al. Chronic Respiratory Diseases and the Outcomes of COVID-19: A Nationwide Retrospective Cohort Study of 39,420 Cases. *J Allergy Clin Immunol Pract* 2021; 9 (7): 2645-2655.e2614.
 - 35 Yamaya M, Nishimura H, Deng X, Sugawara M, Watanabe O, Nomura K et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. *Respir Investig* 2020; 58 (3): 155-168.
 - 36 Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. *Eur Respir J* 2020; 55 (5).
 - 37 Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W et al. The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells. *J Virol* 2020; 95 (1).
 - 38 Schultze A, Walker AJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP et al. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. *Lancet Respir Med* 2020; 8 (11): 1106-1120.
 - 39 Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. *Am J Epidemiol* 2017; 186 (9): 1026-1034.

Figure legends

Figure. 1 Association between the infection rate, hospitalized rate and mortality of COVID-19 and allergic rhinitis/asthma. (A) COVID-19 infection; (B) COVID-19 Hospitalization; (C) COVID-19 mortality. Adjusted for sex, age, Townsend deprivation index, education, current employment status, BMI, ethnic background, smoking status (pack year) and drinking status, and preexisting comorbidities (e.g., diabetes, circulatory diseases, fracture, lower respiratory disease, upper gastrointestinal diseases, renal diseases, dementia, arthritis and certain immune disorders). The x-axis indicates a log-scale. AR*allergic rhinitis.

Figure. 2 Association between long-term control of AR/asthma medications (antihistamine, systemic glucocorticoids, inhaled corticosteroids and β 2 adrenoceptor agonists) and the clinical outcomes of COVID-19 in patients with AR/asthma. (A) COVID-19 infection; (B) COVID-19 hospitalization; (C) COVID-19 mortality. Adjusted for sex, age, Townsend deprivation index, education, BMI, ethnic background, current employment status, smoking status (pack year), drinking status, and preexisting comorbidities (e.g., diabetes, circulatory diseases, fracture, lower respiratory disease, upper gastrointestinal diseases, renal diseases, dementia, arthritis and certain immune disorders). The x-axis indicates a log-scale. AR*allergic rhinitis; AR/Asthma* either Asthma or AR group

Table 1. Clinical and demographic characteristics of all study subjects (n=70557).

Covariate		COVID-19 infection				COVID-19 hospitalization				COVID-19 mortality			
		Total n=70557 (%)	No n=54867 (%)	Yes n=15690 (%)	p-value	Total n=15690 (%)	No n=10775 (%)	Yes n=4915 (%)	p-value	Total n=15690 (%)	No n=15054 (%)	Yes n=636 (%)	p-value
Group	AR	3201 (5)	2656 (5)	545 (3)	<0.001	545 (3)	419 (4)	126 (3)	<0.001	545 (3)	531 (4)	14 (2)	0.0011
	Asthma	8624 (12)	6801 (12)	1823 (12)		1823 (12)	1042 (10)	781 (16)		1823 (12)	1720 (11)	103 (16)	
	Both	1407 (2)	1151 (2)	256 (2)		256 (2)	177 (2)	79 (2)		256 (2)	247 (2)	9 (1)	
	Control	57325 (81)	44259 (81)	13066 (83)		13066 (83)	9137 (85)	3929 (80)		13066 (83)	12556 (83)	510 (80)	
Sex	Female	37725 (53)	29441 (54)	8284 (53)	0.058	8284 (53)	5953 (55)	2331 (47)	<0.001	8284 (53)	8072 (54)	212 (33)	<0.001
	Male	32832 (47)	25426 (46)	7406 (47)		7406 (47)	4822 (45)	2584 (53)		7406 (47)	6982 (46)	424 (67)	
Age	Mean (SD)	67.8 (8.3)	68.7 (8)	64.4 (8.6)	<0.001	64.4 (8.6)	62.8 (8)	68 (8.8)	<0.001	64.4 (8.6)	64 (8.5)	74 (5.6)	<0.001
	Median (Min,Max)	69.3 (49.5,85.2)	70.5 (49.5,85.2)	63.5 (49.5,82.9)	<0.001	63.5 (49.5,82.9)	61.5 (49.5,82.6)	69.9 (49.7,82.9)	<0.001	63.5 (49.5,82.9)	62.9 (49.5,82.7)	75.7 (52.9,82.9)	<0.001
Ethnic	Non-white	4583 (7)	2947 (5)	1636 (10)	<0.001	1636 (10)	1123 (10)	513 (11)	0.95	1636 (10)	1582 (11)	54 (9)	0.12
	White	65576 (93)	51617 (95)	13959 (90)		13959 (90)	9598 (90)	4361 (89)		13959 (90)	13382 (89)	577 (91)	
	Missing	398	303	95		95	54	41		95	90	5	
BMI	Normal/Under	20185 (29)	16120 (30)	4065 (26)	<0.001	4065 (26)	3098 (29)	967 (20)	<0.001	4065 (26)	3962 (27)	103 (17)	<0.001
	Obese	19923 (28)	15031 (28)	4892 (31)		4892 (31)	2994 (28)	1898 (39)		4892 (31)	4616 (31)	276 (44)	
	Overweight	29933 (43)	23340 (43)	6593 (42)		6593 (42)	4612 (43)	1981 (41)		6593 (42)	6350 (43)	243 (39)	
	Missing	516	376	140		140	71	69		140	126	14	
Employment	Employed	40585 (58)	29976 (55)	10609 (68)	<0.001	10609 (68)	8092 (76)	2517 (52)	<0.001	10609 (68)	10426 (70)	183 (29)	<0.001
	Other	6238 (9)	4673 (9)	1565 (10)		1565 (10)	973 (9)	592 (12)		1565 (10)	1493 (10)	72 (11)	
	Retired	23265 (33)	19865 (36)	3400 (22)		3400 (22)	1633 (15)	1767 (36)		3400 (22)	3021 (20)	379 (60)	
	Missing	469	353	116		116	77	39		116	114	2	
Education	Mean (SD)	14.6 (5.2)	14.6 (5.2)	14.4 (5.2)	<0.001	14.4 (5.2)	14.8 (5)	13.7 (5.4)	<0.001	14.4 (5.2)	14.5 (5.1)	12.6 (5.4)	<0.001
	Median (Min,Max)	15 (7,20)	15 (7,20)	15 (7,20)		15 (7,20)	15 (7,20)	15 (7,20)		15 (7,20)	15 (7,20)	10 (7,20)	
	Missing	1583	1212	371		371	227	144		371	346	25	
Townsend deprivation index	High	15441 (22)	11249 (21)	4192 (27)	<0.001	4192 (27)	2674 (25)	1518 (31)	<0.001	4192 (27)	3984 (26)	208 (33)	0.0021
	Low	13320 (19)	10893 (20)	2427 (15)		2427 (15)	1749 (16)	678 (14)		2427 (15)	2340 (16)	87 (14)	
	Median	41705 (59)	32654 (60)	9051 (58)		9051 (58)	6336 (59)	2715 (55)		9051 (58)	8711 (58)	340 (54)	
	Missing	91	71	20		20	16	4		20	19	1	
Smoking Status	Current	7601 (11)	5816 (11)	1785 (11)	<0.001	1785 (11)	1156 (11)	629 (13)	<0.001	1785 (11)	1693 (11)	92 (15)	<0.001
	Never	36525 (52)	28225 (52)	8300 (53)		8300 (53)	6017 (56)	2283 (47)		8300 (53)	8072 (54)	228 (36)	
	Previous	25924 (37)	20423 (37)	5501 (35)		5501 (35)	3544 (33)	1957 (40)		5501 (35)	5193 (35)	308 (49)	
	Missing	507	403	104		104	58	46		104	96	8	
Smoking (Pack year)	Mean (SD)	11(16.4)	11.2 (16.6)	10.5 (16)	0.0042	10.5 (16)	8.9 (13.8)	14 (19.5)	<0.001	10.5 (16)	10.1 (15.5)	20.2 (23.5)	<0.001
	Missing	504	402	102		102	58	44		102	94	8	
Drinking Status	Current	63947 (91)	49925 (91)	14022 (90)	<0.001	14022 (90)	9777 (91)	4245 (87)	<0.001	14022 (90)	13479 (90)	543 (86)	<0.001
	Never	3494 (5)	2525 (5)	969 (6)		969 (6)	614 (6)	355 (7)		969 (6)	926 (6)	43 (7)	
	Previous	2827 (4)	2191 (4)	636 (4)		636 (4)	348 (3)	288 (6)		636 (4)	591 (4)	45 (7)	
	Missing	289	226	63		63	36	27		63	58	5	

AR: allergic rhinitis. Data involving pre-existing comorbidities are presented in Table E1.

Table 2. Univariable and multivariable analysis for the infection rate, hospitalization rate and mortality of COVID-19 in allergic rhinitis (AR) and/or asthma participants. P-values refer to comparison between each category and the reference category.

Outcome		Univariable analysis			Multivariable analysis		
		Number	RR (95%CI)	p-value	Number	RR (95%CI)	p-value
COVID-19 infection	Controls	57325	Reference	-	54685	Reference	-
	AR	3201	0.75 (0.69-0.81)	<0.001	3101	0.78 (0.71-0.85)	<0.001
	Asthma	8624	0.93 (0.88-0.97)	0.003	8121	0.96 (0.91-1.01)	0.109
	Both	1407	0.80 (0.71-0.9)	<0.001	1357	0.81 (0.72-0.92)	0.001
COVID-19 hospitalization	Controls	13066	Reference	-	12424	Reference	-
	AR	545	0.77 (0.64-0.92)	0.004	534	0.95 (0.79-1.13)	0.548
	Asthma	1823	1.42 (1.32-1.54)	<0.001	1701	1.1 (1.01-1.19)	0.032
	Both	256	1.03 (0.82-1.28)	0.82	246	1.06 (0.84-1.33)	0.636
COVID-19 mortality	Controls	13066	Reference	-	12424	Reference	-
	AR	545	0.66 (0.39-1.12)	0.12	534	1.17 (0.67-2.04)	0.58
	Asthma	1823	1.45 (1.17-1.79)	0.001	1701	0.9 (0.72-1.14)	0.401
	Both	256	0.90 (0.47-1.74)	0.76	246	1.23 (0.61-2.48)	0.567

*Model****: Adjusted for age, gender, Townsend deprivation index, education, BMI, ethnic background, smoking status (smoking experience and pack year) and drinking status, and preexisting comorbidities (e.g., diabetes, circulatory diseases, fracture, lower respiratory disease, upper gastrointestinal diseases, renal diseases, dementia, arthritis and certain immune disorders).*

Table. 3 The infection rate, hospitalization rate and mortality of COVID-19 among participants who used long-term medications (antihistamine, glucocorticoids, inhaled corticosteroids, β 2 adrenoceptor agonists) to control allergic rhinitis (AR) or asthma.

Medication	Variable	COVID-19 infection (n=2540/13232)			COVID-19 hospitalization (n=945/2624)			COVID-19 mortality (n=122/2624)		
		Number	RR (95%CI)	p-value	Number	RR (95%CI)	p-value	Number	RR (95%CI)	p-value
Antihistamine	No	11732	Reference	0.656	2309	Reference	0.302	2309	Reference	0.891
	Yes	847	1.04 (0.89-1.21)		172	1.14(0.89-1.45)		172	0.95 (0.44-2.05)	
Systemic Glucocorticoids	No	10904	Reference	0.922	2180	Reference	0.685	2180	Reference	0.726
	Yes	1675	0.99 (0.88-1.12)		301	0.96 (0.79-1.16)		301	0.91 (0.55-1.52)	
Glucocorticoid nasal sprays	No	11823	Reference	0.649	2348	Reference	0.328	2348	Reference	0.23
	Yes	756	0.96 (0.81-1.14)		133	0.85 (0.62-1.18)		133	0.42 (0.1-1.72)	
β 2 adrenoceptor agonists	No	11689	Reference	0.104	2294	Reference	0.736	2294	Reference	0.321
	Yes	890	1.13 (0.97-1.32)		187	0.96 (0.77-1.21)		187	1.31 (0.77-2.23)	

*Model****: Adjusted for sex, age, Townsend deprivation index, education, BMI, ethnic background, smoking status (smoking experience and pack year), drinking status, and preexisting comorbidities (e.g., diabetes, circulatory diseases, fracture, lower respiratory disease, upper gastrointestinal diseases, renal diseases, dementia, arthritis and certain immune disorders). Not that β 2 adrenoceptor agonists were only prescribed for asthma, not AR.*

(A) COVID-19 infection

Group	Number	RR (95% CI)	p value
Control	54685	1(1-1)	
AR	3101	0.78(0.71-0.85)	<0.001
Asthma	8121	0.96(0.91-1.01)	0.109
Both	1357	0.81(0.72-0.92)	0.001


(B) COVID-19 hospitalization

Group	Number	RR (95% CI)	p value
Control	12424	1(1-1)	
AR	534	0.95(0.79-1.13)	0.548
Asthma	1701	1.1(1.01-1.19)	0.032
Both	246	1.06(0.84-1.33)	0.636


(C) COVID-19 mortality

Group	Number	RR (95% CI)	p value
Control	12424	1(1-1)	
AR	534	1.17(0.67-2.04)	0.58
Asthma	1701	0.9(0.72-1.14)	0.401
Both	246	1.23(0.61-2.48)	0.567

(A)



(B)



(C)

